Related Experiment Video

Updated: Jun 21, 2026

Use of a Piglet Model for the Study of Anesthetic-induced Developmental Neurotoxicity (AIDN): A Translational Neuroscience Approach
06:38

Use of a Piglet Model for the Study of Anesthetic-induced Developmental Neurotoxicity (AIDN): A Translational Neuroscience Approach

Published on: June 11, 2017

Pediatric pharmacology in the first year of life

Anita Sumpter1, Brian J Anderson

  • 1Departments of Anaesthesia and Intensive Care, Auckland Children's Hospital, Auckland, New Zealand.

Current Opinion in Anaesthesiology
|July 14, 2009
PubMed

Insights

Understanding early-life pharmacokinetic and pharmacodynamic changes in pediatric anesthesia is crucial for safe drug administration. Mechanistic models aid in optimizing drug therapy and reducing toxicity in infants.

Area of Science:

  • Pediatric Anesthesiology
  • Pharmacokinetics
  • Pharmacodynamics
  • Pharmacogenomics

Background:

  • Toxicity and drug use in pediatric anesthesia remain significant concerns for anesthesiologists.
  • Key developmental changes in pharmacokinetics, pharmacodynamics, and pharmacogenomics occur within the first year of life.
  • Understanding these early developmental changes is essential for improving drug efficacy and safety in infants.

Purpose of the Study:

  • To review the developmental pharmacokinetic, pharmacodynamic, and pharmacogenomic changes in infants.
  • To explore how these changes impact drug use and toxicity in pediatric anesthesia.
  • To highlight the importance of mechanistic models in studying infant pharmacokinetics.

Main Methods:

  • Review of current literature on pediatric drug metabolism and disposition.
  • Analysis of growth and maturation influences on drug clearance in infants.
  • Examination of hepatic phase II (glucuronidation) and phase I metabolic processes.
  • Discussion of pharmacogenomic variations and their impact in neonates.
  • Assessment of challenges in defining pharmacodynamic differences and measures in infants.

Main Results:

  • Hepatic phase II enzyme maturation (glucuronidation) parallels glomerular filtration maturation in the first year.
  • Phase I metabolic processes appear accelerated in infants.
  • Pharmacogenomic differences may be evident early in the neonatal period.
  • Pharmacodynamic differences in infancy are poorly understood due to limited research and effective measures.
  • Mechanistic models provide a framework for studying pharmacokinetic alterations in infants.

Conclusions:

  • Mechanistic models are valuable for understanding pharmacokinetic changes during infancy.
  • Improved understanding of these changes can lead to a target concentration approach for drug therapy.
  • This approach has the potential to reduce drug toxicity in pediatric patients.
  • Further research is needed to define pharmacodynamic measures and targets in infants.
Abstract

More Related Videos

Assessment and Evaluation of the High Risk Neonate: The NICU Network Neurobehavioral Scale19:15

Assessment and Evaluation of the High Risk Neonate: The NICU Network Neurobehavioral Scale

Published on: August 25, 2014

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
Factors Affecting Drug Response: Overview01:21

Factors Affecting Drug Response: Overview

When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...